An official website of the United States government
French Bladder Cancer Study (FBCS)
Study Name: French Bladder Cancer Study (FBCS)
Principal Investigators:
INSERM/CNRS: Simone Benhamou, Alain Sarasin
DBS: Agnès Laplanche
Additional researchers:
Stefan Michiels (DBS)
Thomas Boulet (DBS)
Philippe Dessen (CNRS)
Institution/s:
INSERM U794 and CNRS FRE2939
Institut Gustave Roussy, Villejuif France
Institution/s address:
INSERMU794/CNRS FRE2939
Institut Gustave Roussy
Espace Maurice Tubina (-1)
94805 Villejuif, France
Department of Biostatistics and Epidemiology (DBS)
Institut Gustave Roussy
Rue Camille Desmoulins,
94805 Villejuif cedex, France
Key References:
Benhamou S. et al. Mutagenesis. 2003 Sep;18(5):445-8
Study Design: Hospital-based case control
Matching factors: Age, gender and hospital
Country: France
ICD-0-3 morphology codes: 81203
Follow up of cases? Yes (but not for all cases)
Expected time of follow-up? 60 months
Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)
| Cases | Controls | |
|---|---|---|
| Years of enrollment | 1997-2001 | 1997-2001 |
| Source population | 3 general hospitals in Paris | 3 general hospitals in Paris |
| Response rate (enrolled/eligible) | 95% | 95% |
| Total number enrolled | 201 | 322 |
| Subjects with DNA | 195 | 320 |
| Ethnic origin | 100% Caucasian | 100% Caucasian |
| Age: mean (range) | 66 (30-89) | 67 (34-92) |
| Gender: % males | 84% | 85% |
| Questionnaire data | Cases | Controls |
|---|---|---|
| Demographics (age, sex, ethnicity, region, education etc..) | x | x |
| Active smoking | x | x |
| Passive smoking | - | - |
| Occupational exposures | x | x |
| Residential history | - | - |
| Water chlorination byproducts | - | - |
| Arsenic exposure | - | - |
| Other environmental exposures | - | - |
| Hair dye use | - | - |
| Drug use | - | - |
| Medical History | - | - |
| Family History | - | - |
| Quality of life | - | - |
| Diet/nutrition | - | - |
| Caffeine intake | x | x |
| Fluid intake | - | - |
| Urine pH measurements | - | - |
| Other information, please specify | - | - |
| Biological Samples | Cases | Controls |
|---|---|---|
| Blood DNA | x | x |
| Buccal DNA | - | - |
| Serum/plasma | - | - |
| Cryopreserved whole blood / lymphocytes | - | - |
| Red blood cells | - | - |
| Urine samples | - | - |
| Toenail clippings | - | - |
| Others, please specify | - | - |
| Paraffin tissue blocks | x | |
| Frozen tissue | - |
| For Cases Only | |
| Information at time of diagnosis | Cases |
|---|---|
| Histological confirmation | x |
| Number of tumors | x |
| Tumor site | - |
| Tumor size | x |
| Tumor grade | x |
| Growth pattern | - |
| Treatment of primary tumor | x |
| Stage | x |
| Other information, please specify | - |
| Follow-up information | Cases |
|---|---|
| Treatment information | x |
| Tumor recurrence | x |
| Tumor progression | x |
| Survival | x |
| Histological confirmation | x |
| Number of tumors | - |
| Tumor site | - |
| Tumor size | - |
| Tumor grade | x |
| Growth pattern | - |
| Stage | x |
| Active smoking | - |
| Occupational exposures | - |
| Drug use | - |
| Medical History | - |
| Quality of life | - |
| Caffeine intake | - |
| Fluid intake | - |
| Other information , please specify | - |